{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:42Z","timestamp":1790610822609,"version":"4.1.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We review the current standards of treatment and discuss novel developments in the pathophysiology, diagnosis, outcome prediction and management of anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM disease is a unique form of small vessel vasculitis affecting the glomerular and pulmonary capillaries. It is caused by autoantibodies directed against the \u03b13 chain of type IV collagen, leading to rapidly progressive glomerulonephritis with pulmonary haemorrhage in \u223c50% of cases. Diagnosis relies on clinical features, kidney biopsy showing linear IgG deposition along the GBM, and\/or detection of circulating anti-GBM antibodies. Historically, untreated disease was rapidly fatal, but the introduction of plasma exchange combined with cyclophosphamide and glucocorticoids has significantly improved outcomes, particularly in patients who are not dialysis-dependent at presentation. Dialysis-dependent patients have a lower likelihood of renal recovery, and treatment decisions must consider biopsy findings, clinical severity and potential contraindications to standard immunosuppression. Unlike anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis, relapses are rare in classic anti-GBM disease, and long-term maintenance immunosuppression is not routinely required. However, \u2018double positive\u2019 patients (anti-GBM and ANCA) have a higher relapse risk and require maintenance immunosuppressive treatment. Atypical anti-GBM presentations, including seronegative cases, are now better recognized but their optimal management remains unclear. Future research should define the use of oral versus intravenous cyclophosphamide in anti-GBM disease, clarify the role of rituximab and determine the place of emerging therapies such as imlifidase. Advances in risk stratification and ongoing trials are expected to inform treatment individualization and to improve treatment approaches for this aggressive autoimmune disease.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf190","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T11:49:15Z","timestamp":1758196155000},"page":"42-54","source":"Crossref","is-referenced-by-count":7,"title":["Anti-glomerular basement membrane disease\u2014treatment standard"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-8770","authenticated-orcid":false,"given":"Stephen P","family":"McAdoo","sequence":"first","affiliation":[{"name":"Vasculitis Centre, Dept of Immunology & Inflammation, Imperial College London , London ,","place":["UK"]},{"name":"Imperial College Healthcare NHS Trust Vasculitis Clinic, Department of Renal Medicine, , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D","family":"Pusey","sequence":"additional","affiliation":[{"name":"Vasculitis Centre, Dept of Immunology & Inflammation, Imperial College London , London ,","place":["UK"]},{"name":"Imperial College Healthcare NHS Trust Vasculitis Clinic, Department of Renal Medicine, , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"2025122223470154400_bib1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025122223470154400_bib2","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.2215\/CJN.01380217","article-title":"Anti-glomerular basement membrane disease","volume":"12","author":"McAdoo","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025122223470154400_bib3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2025122223470154400_bib4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0038-1669413","article-title":"Antiglomerular basement membrane disease","volume":"39","author":"McAdoo","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"2025122223470154400_bib5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ndt\/gfx057","article-title":"Diagnostic and management challenges in Goodpasture\u2019s (anti-glomerular basement membrane) disease","volume":"33","author":"Henderson","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223470154400_bib6","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ekir.2023.03.010","article-title":"Atypical anti-glomerular basement membrane disease","volume":"8","author":"Bharati","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025122223470154400_bib7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0140-6736(76)93089-0","article-title":"Immunosuppression and plasma-exchange in the treatment of Goodpasture\u2019s syndrome","volume":"307","author":"Lockwood","year":"1976","journal-title":"Lancet"},{"key":"2025122223470154400_bib8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/00005792-198507000-00003","article-title":"Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors","volume":"64","author":"Johnson","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"2025122223470154400_bib9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.7326\/0003-4819-134-11-200106050-00009","article-title":"Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression","volume":"134","author":"Levy","year":"2001","journal-title":"Ann Intern Med"},{"key":"2025122223470154400_bib10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2016.05.015","article-title":"Outcomes of patients with goodpasture syndrome: a nationwide cohort-based study from the French Society of Hemapheresis","volume":"73","author":"Huart","year":"2016","journal-title":"J Autoimmun"},{"key":"2025122223470154400_bib11","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3389\/fimmu.2019.01665","article-title":"Prognostic factors in anti-glomerular basement membrane disease: a multicenter study of 119 patients","volume":"10","author":"Marques","year":"2019","journal-title":"Front Immunol"},{"key":"2025122223470154400_bib12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1159\/000523713","article-title":"Predictors of kidney outcomes of anti-glomerular basement membrane disease in a large chinese cohort","volume":"53","author":"Jia","year":"2022","journal-title":"Am J Nephrol"},{"key":"2025122223470154400_bib13","doi-asserted-by":"publisher","first-page":"2400539","DOI":"10.1080\/0886022X.2024.2400539","article-title":"Plasmapheresis, immunosuppressive therapy and anti-GBM disease prognosis: a cohort study of 107 patients","volume":"46","author":"Liu","year":"2024","journal-title":"Ren Fail"},{"key":"2025122223470154400_bib14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s40620-023-01695-9","article-title":"Therapeutic plasma exchange for anti-glomerular basement membrane disease with dialysis-dependent kidney failure without diffuse alveolar hemorrhage","volume":"36","author":"Watanabe","year":"2023","journal-title":"J Nephrol"},{"key":"2025122223470154400_bib15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the writing committee of the American Society for Apheresis: the ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"2025122223470154400_bib16","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1016\/j.ekir.2024.06.031","article-title":"Immunoadsorption and plasma exchange are comparable in anti-neutrophil cytoplasmic antibodies or anti-glomerular basement membrane removal kinetics","volume":"9","author":"Sallee","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025122223470154400_bib17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.ajkd.2023.12.019","article-title":"Use of immunoadsorption and plasma exchange for treating anti-glomerular basement membrane disease: clinical experience in Germany","volume":"84","author":"von Samson-Himmelstjerna","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2025122223470154400_bib18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/MD.0b013e31822f6f68","article-title":"Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study","volume":"90","author":"Cui","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"2025122223470154400_bib19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025122223470154400_bib20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ekir.2024.12.026","article-title":"Efficacy and safety of rituximab in antiglomerular basement membrane disease","volume":"10","author":"Ivkovic","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2025122223470154400_bib21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5414\/CN107333","article-title":"Anti-glomerular basement membrane disease treated with mycophenolate mofetil, corticosteroids, and plasmapheresis","volume":"80","author":"Mori","year":"2013","journal-title":"Clin Nephrol"},{"key":"2025122223470154400_bib22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/ndt\/15.6.920","article-title":"Goodpasture\u2019s syndrome treated with mycophenolate mofetil","volume":"15","author":"Garcia-Canton","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223470154400_bib23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2169\/internalmedicine.49.2321","article-title":"Successful treatment of resistant antiglomerular basement membrane antibody positivity with mycophenolic acid","volume":"49","author":"Kiykim","year":"2010","journal-title":"Intern Med"},{"key":"2025122223470154400_bib24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/md.0b013e318067da56","article-title":"Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases","volume":"86","author":"Lazor","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"2025122223470154400_bib25","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/ndt\/gfu399","article-title":"Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort","volume":"30","author":"Alchi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223470154400_bib26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2215\/CJN.04290417","article-title":"Predicting outcome in patients with anti-GBM glomerulonephritis","volume":"13","author":"van Daalen","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025122223470154400_bib27","first-page":"75","article-title":"Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis\/Goodpasture\u2019s syndrome","volume":"54","author":"Walker","year":"1985","journal-title":"Q J Med"},{"key":"2025122223470154400_bib28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"key":"2025122223470154400_bib29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/ajkd.2000.8993","article-title":"Immunoadsorption in Goodpasture\u2019s syndrome","volume":"36","author":"Laczika","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"2025122223470154400_bib30","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.ekir.2018.04.015","article-title":"Reversal of dialysis-dependent anti-glomerular basement membrane disease using plasma exchange, glucocorticosteroids, and rituximab","volume":"3","author":"Lemahieu","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2025122223470154400_bib31","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/ckj\/sfw038","article-title":"Multiple recurrences of anti-glomerular basement membrane disease with variable antibody detection: can the laboratory be trusted?","volume":"9","author":"Liu","year":"2016","journal-title":"Clin Kidney J"},{"key":"2025122223470154400_bib32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/ckj\/sfw048","article-title":"Frequently relapsing anti-glomerular basement membrane antibody disease with changing clinical phenotype and antibody characteristics over time","volume":"9","author":"Gu","year":"2016","journal-title":"Clin Kidney J"},{"key":"2025122223470154400_bib33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ki.2012.375","article-title":"Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease","volume":"83","author":"Tang","year":"2013","journal-title":"Kidney Int"},{"key":"2025122223470154400_bib34","first-page":"570","article-title":"Renal transplantation for uncommon diseases. Scientific advisory board of the ERA-EDTA registry. European Renal Association-European Dialysis And Transplant Association","volume":"14","author":"Briggs","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223470154400_bib35","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1111\/j.1600-6143.2006.01502.x","article-title":"Recurrent glomerulonephritis after kidney transplantation","volume":"6","author":"Choy","year":"2006","journal-title":"Am J Transplant"},{"key":"2025122223470154400_bib36","doi-asserted-by":"publisher","first-page":"e14179","DOI":"10.1111\/ctr.14179","article-title":"Long-term outcomes in kidney transplant recipients with end-stage kidney disease due to anti-glomerular basement membrane disease","volume":"35","author":"Singh","year":"2021","journal-title":"Clin Transplant"},{"key":"2025122223470154400_bib37","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.ekir.2021.04.011","article-title":"Recurrence and outcome of anti-glomerular basement membrane glomerulonephritis after kidney transplantation","volume":"6","author":"Coche","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025122223470154400_bib38","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1093\/ndt\/gfs099","article-title":"Venous thromboembolism with concurrent pulmonary haemorrhage in systemic vasculitis","volume":"27","author":"De Sousa","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223470154400_bib39","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1681\/ASN.2010090928","article-title":"Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease","volume":"22","author":"Olson","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025122223470154400_bib40","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"key":"2025122223470154400_bib41","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1681\/ASN.2010090923","article-title":"Membranous nephropathy with crescents","volume":"22","author":"Basford","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025122223470154400_bib42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/ki.2013.364","article-title":"The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy","volume":"85","author":"Jia","year":"2014","journal-title":"Kidney Int"},{"key":"2025122223470154400_bib43","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.ekir.2019.07.021","article-title":"Membranous glomerulonephritis with crescents","volume":"4","author":"Nikolopoulou","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2025122223470154400_bib44","doi-asserted-by":"publisher","first-page":"597863","DOI":"10.3389\/fimmu.2020.597863","article-title":"Absence of anti-glomerular basement membrane antibodies in 200 patients with systemic lupus erythematosus with or without lupus nephritis: results of the GOODLUPUS study","volume":"11","author":"Bourse Chalvon","year":"2020","journal-title":"Front Immunol"},{"key":"2025122223470154400_bib45","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/ckj\/sfs087","article-title":"IgA-mediated anti-glomerular basement membrane disease: an uncommon mechanism of Goodpasture\u2019s syndrome","volume":"5","author":"Moulis","year":"2012","journal-title":"Clin Kidney J"},{"key":"2025122223470154400_bib46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/ndt\/13.4.935","article-title":"Anti-glomerular basement membrane (GBM)-antibody-mediated disease with normal renal function","volume":"13","author":"Ang","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223470154400_bib47","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/sj.ki.5002525","article-title":"Antiglomerular basement membrane disease with normal renal function","volume":"72","author":"Cui","year":"2007","journal-title":"Kidney Int"},{"key":"2025122223470154400_bib48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1053\/j.ajkd.2013.08.032","article-title":"Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease","volume":"63","author":"Ohlsson","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025122223470154400_bib49","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.kint.2016.02.001","article-title":"The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis","volume":"89","author":"Nasr","year":"2016","journal-title":"Kidney Int"},{"key":"2025122223470154400_bib50","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/j.ajkd.2023.11.003","article-title":"Atypical anti-glomerular basement membrane nephritis: a case series from the French nephropathology group","volume":"83","author":"Chauveau","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2025122223470154400_bib51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ajt.2023.09.007","article-title":"Recurrent atypical antiglomerular basement membrane nephritis in the kidney transplant","volume":"24","author":"Mignano","year":"2024","journal-title":"Am J Transplant"},{"key":"2025122223470154400_bib52","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4103\/ijn.IJN_113_16","article-title":"Circulating monoclonal IgG1-kappa antibodies causing anti-glomerular basement membrane nephritis","volume":"27","author":"Vankalakunti","year":"2017","journal-title":"Indian J Nephrol"},{"key":"2025122223470154400_bib53","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1056\/NEJMoa0910500","article-title":"Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis","volume":"363","author":"Pedchenko","year":"2010","journal-title":"N Engl J Med"},{"key":"2025122223470154400_bib54","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1053\/ajkd.2002.31997","article-title":"Renal transplant in patients with Alport\u2019s syndrome","volume":"39","author":"Byrne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2025122223470154400_bib55","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1399-3046.2006.00528.x","article-title":"Renal transplantation in patients with Alport syndrome","volume":"10","author":"Kashtan","year":"2006","journal-title":"Pediatr Transplant"},{"key":"2025122223470154400_bib56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1523-1755.2004.00428.x","article-title":"Retransplantation in Alport post-transplant anti-GBM disease","volume":"65","author":"Browne","year":"2004","journal-title":"Kidney Int"},{"key":"2025122223470154400_bib57","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1681\/ASN.2012020148","article-title":"Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy","volume":"24","author":"Savige","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025122223470154400_bib58","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/ckj\/sfu086","article-title":"Maternal, pregnancy and fetal outcomes in de novo anti-glomerular basement membrane antibody disease in pregnancy: a systematic review","volume":"7","author":"Thomson","year":"2014","journal-title":"Clin Kidney J"},{"key":"2025122223470154400_bib59","first-page":"407","article-title":"Goodpasture\u2019s syndrome in early pregnancy: a case report","volume":"15","author":"Qin","year":"2018","journal-title":"Exp Ther Med"},{"key":"2025122223470154400_bib60","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/thoraxjnl-2016-208441","article-title":"Lesson of the month: selective use of cyclophosphamide in pregnancy for severe autoimmune respiratory disease","volume":"71","author":"Nelson-Piercy","year":"2016","journal-title":"Thorax"},{"key":"2025122223470154400_bib61","doi-asserted-by":"publisher","first-page":"e257767","DOI":"10.1136\/bcr-2023-257767","article-title":"Anti-GBM disease in pregnancy","volume":"17","author":"Kafagi","year":"2024","journal-title":"BMJ Case Rep"},{"key":"2025122223470154400_bib62","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00467-024-06521-3","article-title":"Etiology, clinical profile, and outcomes of crescentic glomerulonephritis in children: a systematic review","volume":"40","author":"Meena","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"2025122223470154400_bib63","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00467-021-05333-z","article-title":"Anti-glomerular basement membrane disease in children: a brief overview","volume":"37","author":"Dowsett","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"2025122223470154400_bib64","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00467-024-06512-4","article-title":"Outcome of rituximab treatment in children with non-dialysis-dependent anti-GBM disease","volume":"40","author":"Klaus","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"2025122223470154400_bib65","doi-asserted-by":"publisher","first-page":"100590","DOI":"10.1016\/j.jbc.2021.100590","article-title":"Collagen IV(alpha345) dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture\u2019s and Alport diseases","volume":"296","author":"Pokidysheva","year":"2021","journal-title":"J Biol Chem"},{"key":"2025122223470154400_bib66","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1681\/ASN.2018050519","article-title":"Inhibitory anti-peroxidasin antibodies in pulmonary-renal syndromes","volume":"29","author":"McCall","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2025122223470154400_bib67","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1681\/ASN.2020101431","article-title":"Laminin-521 is a novel target of autoantibodies associated with lung hemorrhage in anti-GBM disease","volume":"32","author":"Shen","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2025122223470154400_bib68","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature22329","article-title":"Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells","volume":"545","author":"Ooi","year":"2017","journal-title":"Nature"},{"key":"2025122223470154400_bib69","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1681\/ASN.2022050581","article-title":"Risk stratification to predict renal survival in anti-glomerular basement membrane disease","volume":"34","author":"Floyd","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025122223470154400_bib70","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/ndt\/gfq115","article-title":"Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes","volume":"25","author":"Yang","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2025122223470154400_bib71","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.kint.2019.06.019","article-title":"The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease","volume":"96","author":"Soveri","year":"2019","journal-title":"Kidney Int"},{"key":"2025122223470154400_bib72","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1681\/ASN.2021111460","article-title":"Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: an open-label phase 2a study","volume":"33","author":"Uhlin","year":"2022","journal-title":"J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf190\/64314016\/gfaf190.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/1\/42\/64314016\/gfaf190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/1\/42\/64314016\/gfaf190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T04:47:10Z","timestamp":1766465230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/1\/42\/8257581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,18]]},"published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf190","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,18]]}}}